Potential release of toxic metal elements from Essure ® device in symptomatic patients: first results of the French Ablimco cohort

Since the decision to halt sales of the Essure ® implants for permanent birth control in December 2018 (Bayer©, Leverkusen, Germany), many patients have complained of unspecific symptoms, such as gynecological disorders (pain, menorrhagia), but also broad extrapelvic symptoms (persistent asthenia and fatigue, heart palpitations, tinnitus, prur itus, joint and / or muscularis pain, skin rashes, digestive disorders) [1]. Several studies have shown an improvement in symptomatology and quality of life after Essure® removal in symptomatic patients [1,2].
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Tags: Full length article Source Type: research